Latest news with #transplantation
Gizmodo
4 days ago
- Health
- Gizmodo
Diabetic Man With Gene-Edited Cells Produces His Own Insulin—No Transplant Drugs Required
A new case study offers a tantalizing glimpse into the potential future of transplantation medicine. A man with type 1 diabetes is now able to make his own insulin thanks to a transplant of gene-edited pancreatic cells—a transplant that hasn't required the typical drugs used to avoid rejection. Scientists in Sweden and the U.S. conducted the research, published this week in the New England Journal of Medicine. The 42-year-old man with long-standing diabetes was given donated islet cells that were genetically modified via CRISPR to prevent immune rejection. Roughly four months after the procedure, his fully gene-edited cells have continued to produce insulin without provoking an immune response. 'Our study, although preliminary, suggests that immune evasion is an alternative concept for the circumvention of allorejection,' the authors wrote in the paper. A New Diabetes Treatment Is on the Horizon—But It Involves Poop People with type 1 diabetes have immune systems that destroy the pancreatic cells responsible for making insulin. The condition can be managed with regular doses of synthetic insulin, but people's health still tends to worsen over time. Recently, scientists have been studying whether donated islet cell transplants can provide a self-sustained replacement supply of insulin for type 1 diabetics—an effective cure, in other words, provided the cells can survive long-term. Early clinical trials of the technology have looked promising so far, but these transplants still require lifelong immunosuppressive therapy to ensure the host's body doesn't go after the donated cells. Effective as these drugs are, they have their well-known drawbacks, such as weakening people's immunity to actual threats like infections. The study researchers have been experimenting with a unique approach to sidestep the need for these drugs. They first tested it on mice and monkeys, with this new case being the first test in humans. They created three specific edits in the donated cells, all intended to quiet the most likely responses from the immune system. Two of the edits deplete the cells' supply of HLA class I and II antigens, proteins that tell our T cells whether another cell is foreign or not. A third edit causes the donated cells to make more of another protein called CD47 that inhibits the activity of other immune cells that would normally target them. The researchers injected the modified cells into the man's forearm. The edits weren't completely successful in some of the cells, and the man's immune system quickly killed off these cells. But as hoped, his body left the fully edited cells alone, even without immunosuppressants. The surviving cells produced insulin as normal, and the man appeared to be doing well 12 weeks later. He did experience several adverse events, but none were serious or linked to the transplanted cells themselves (he had mildly inflamed veins where a catheter was placed, for instance). This study is only a proof of concept, geared more at showing the procedure can be done safely than at proving it actually works. The man was given a relatively low dose of the donated cells, likely too low for his body to produce enough insulin on its own to no longer need treatment. Follow-up is also needed to know whether these cells can survive long-term. In Medical First, Woman's Type 1 Diabetes Seemingly Cured by Stem Cells But there's much to be encouraged about. And it's the latest sign that scientists are truly on the verge of making type 1 diabetes curable. Other research teams have shown early success in using similar transplants to cure the condition, including some that have also avoided needing immunosuppressant therapy.
Yahoo
01-08-2025
- Business
- Yahoo
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
High-impact datasets across heart, kidney and lung at WTC follows two major publications in the American Journal of Transplantation in the last three months AUSTIN, Texas, August 01, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA. The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive collections of data on Natera's Prospera test to date. Highlights include five oral presentations and 11 poster sessions featuring evidence from high-impact studies that support the use of Natera's products, such as: Multiple abstracts from the Trifecta series of studies, including three oral presentations which evaluated Prospera's performance across kidney, heart and lung transplantation. Two posters tied to recently published studies in the American Journal of Transplantation: (1) The prospective, multi-center PEDAL clinical trial, which demonstrated Prospera Kidney's ability to predict long-term outcomes following rejection; and (2) a study on Prospera Heart with Donor Quantity Score (DQS), highlighting its robust performance in detecting allograft rejection. An oral presentation detailing Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection with anti-CD38 monoclonal antibody therapy. These findings were published earlier this month in Kidney International Reports. "We are proud to share 16 presentations across kidney, heart and lung at this major global conference," said Sangeeta Bhorade, M.D., chief medical officer of organ health at Natera. "These new presentations and recent peer-reviewed publications underscore the clinical value of Prospera and affirm our leadership in advancing transplant care through innovation and science." Full list of presentations at WTC include: August 3, 5:35 PM PT | Presentation # OA11.8 (Oral Presentation)Presenter: Patrick T. Gauthier, Study: dd-cfDNA Correlates with T Cell-Mediated Rejection and Parenchymal Injury in Mucosal Biopsies of Lung Transplants August 4, 3:30 PM PT | Presentation # P2.07.92Presenter: Vasanthi Balaraman, of Broad Gene Panel for Kidney Disease in Kidney Transplant Donor Selection: A Case Study August 4, 3:30 PM PT | Presentation # P2.07.165Presenter: Yasar Caliskan, Regarding Use of Genetic Testing in Living Donor Candidate Evaluation: A Survey of US Transplant Center Staff August 4, 3:30 PM PT | Presentation # P2.07.198Presenter: Katelynn S. Madill-Thomsen, All DSA Positive Allows Existing Banff Guidelines to Diagnose Many More Cases of Histologic ABMR Currently Missed Only Because They Are DSA-Negative August 4, 4:41 PM PT | Presentation # OA18.2 (Oral Presentation)Presenter: Krista Lentine, M.D., Practice and Challenges in Managing the Costs of Kidney Paired Donation: A Survey of US Transplant Professionals August 5, 3:30 PM PT | Presentation # P3.03.50Presenter: Suphamai Bunnapradist, the Response to Treatment of Kidney Allograft Rejection with Donor-Derived Cell-Free DNA August 5, 3:30 PM PT | Presentation # P3.03.55Presenter: Paul J. Kim, M.D.A Two-Threshold Algorithm Using Donor-Derived Cell-Free DNA Fraction and Quantity to Detect Acute Rejection After 21 Days Post Heart Transplantation August 5, 3:30 PM PT | Presentation # P3.03.56Presenter: Alan Betensley, M.D., BSE, FCCPMonitoring Changes in Donor-Derived Cell-Free DNA Levels in Treated Lung Allograft Rejection: Pilot Data August 5, 3:30 PM PT | Presentation # P3.03.57Presenter: David J. Ross, M.D., FCCP, FASTCell-Free DNA Does Not Discriminate Acute Rejection from Infection After Lung Transplant: Pilot Study August 5, 3:30 PM PT | Presentation # P3.03.58Presenter: Katherine Vandervest, M.D.'Baseline Lung Allograft Dysfunction' is Associated with Different Cell-Free DNA Dynamics After Lung Transplantation August 5, 3:30 PM PT | Presentation # P3.03.59Presenter: Eileen Hsich, Cell-Free DNA is Not Associated with White Blood Cell Count in Heart Transplant Recipients August 5, 3:30 PM PT | Presentation # P3.03.60Presenter: Navchetan Kaur, of dd-cfDNA Levels in Patients Undergoing Repeat Kidney Transplantation August 5, 3:30 PM PT | Presentation # P3.07.177Presenter: Ziad S. Zaky, Machine Learning with Dynamic Time Warping Helps Understand Longitudinal dd-cfDNA Trajectories in Kidney Transplant Patients August 5, 4:41 PM PT | Presentation # OA36.2 (Oral Presentation)Presenter: Katelynn S. Madill-Thomsen, Relationships Among Tests for Heart Transplant Antibody-Mediated Rejection August 6, 8:44 AM PT | Presentation # OA50.4 (Oral Presentation)Presenter: Katelynn S. Madill-Thomsen, the Hierarchy of Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection August 6, 9:20 AM PT | Presentation # OA50.8 (Oral Presentation)Presenter: Wai-Choong Lye, Monoclonal Antibody Daratumumab for the Treatment of Chronic Active-Antibody Mediated Kidney Allograft Rejection About NateraNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking StatementsAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
06-07-2025
- Business
- Yahoo
FDA Grants Orphan Drug Designation To Sanofi's (SNY) Riliprubart
Sanofi (NASDAQ:SNY) is one of the . On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation. The FDA grants orphan drug designation to drugs aimed at treating rare diseases or conditions affecting fewer than 200,000 people in the US. This is a significant milestone for Sanofi (NASDAQ:SNY) as it provides benefits including tax credits, user fee waivers, and market exclusivity upon approval. Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. Riliprubart is currently being evaluated in multiple clinical trials across different indications, including transplant and neurology. The phase 2 study is underway to assess its efficacy in kidney transplant recipients. Sanofi (NASDAQ:SNY) is also conducting two phase 3 trials investigating Riliprubart in chronic inflammatory demyelinating polyneuropathy. Sanofi (NASDAQ:SNY) is a leading healthcare company headquartered in France. It focuses on improving patient health through the research, development, manufacturing, and marketing of a wide range of therapeutic solutions. While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Exclusive Outlook: HLA Typing Market Poised for 6.7% CAGR Growth Through 2030, Reaching $1.7 Billion on Rising Transplant Demand
CHICAGO, June 24, 2025 /PRNewswire/ -- The HLA Typing Market size is projected to be valued at USD 1,097.9 million in 2023 and reach USD 1.7 billion by 2030, growing at a CAGR of 6.7% according to a new report by The Research Insights. Factors such as rising use of infectious diseases and rising number of patients suffering from end-stage organ failure are fuelling the growth of the HLA typing market. Transplantation techniques have advanced over the years which has led to increase in number of people undergoing transplants and thus, increasing the demand for accurate and reliable HLA typing. Increased investments by both private and public sector on transplantation and increased awareness campaigns have encouraged more individuals to go for organ donation and transplantation. Increased focus on personalized medicine, rising advancements in molecular diagnostics and rising number of chronic disorders leading to organ failure are expected to drive the HLA typing market. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the HLA Typing Market growth of 6.7% comprises a vast array of Product, Application, Technique, End-User and Geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global HLA Typing Market, Download FREE Sample Pages: Market Overview and Growth Trajectory: HLA Typing Market Growth: According to an exhaustive report by The Research Insights, the HLA Typing Market is experiencing significant growth. The rapid growth of the next-generation sequencing (NGS) has led to the rising adoption of HLA typing technologies that allow for high-resolution and high-throughput HLA typing with higher accuracy. The applications of NGS have made the HLA typing more effective in transplantation and personalized medicine. The rising prevalence of autoimmune diseases and cancer has also led to a demand for precise HLA typing in immunotherapy and companion diagnostics. The increasing number of organ transplant procedures, the rising awareness of donor-recipient compatibility, and other factors have led to a consistent demand for high-end HLA matching solutions. Trends such as decentralized testing with point-of-care genetic platforms and integration of artificial intelligence for data interpretation have also influenced the market. Investments in the biopharmaceutical R&D, especially in the area of vaccine development and cell therapies, have raised the strategic importance of HLA typing in preclinical and clinical phases, and that will continue to be a major component in the evolving field of precision healthcare. The Increasing Need for Organ and Stem Cell Transplantation: The market for human leukocyte antigen (HLA) typing has seen a considerable rise due to the increasing number of organ and hematopoietic stem cell (bone marrow) transplants across the globe. HLA typing is vital in determining the compatibility between the donor and the recipient in order to reduce the chances of transplant rejection and ensure a better rate of graft survival. The prevalence of end-stage renal disease, liver failure, leukemia, lymphoma, and other immune system disorders has consistently been on the rise and has led to the demand for an increasing number of organ and stem cell transplants. According to the Global Observatory on Donation and Transplantation (GODT), the number of organ transplantations has seen a steady rise in recent years, and that of kidney and liver transplants were found to be the most in volume. HLA typing has a crucial role in the assessment before the transplantation, and therefore, is an indispensable component in the field of transplantation. The growth of transplantation registries and the awareness campaigns aimed at encouraging organ donation have also led to the increased demand for HLA testing, both for the living and the deceased. For Detailed Market Insights, Visit: Technological Advances in Molecular Diagnostics: The advances in molecular biology and genomic sequencing have helped in significantly increasing the accuracy, speed, and efficiency of HLA typing. Most of the conventional methods of serological typing have been either substituted or supported by PCR-based methods (PCR-SSP, PCR-SSO), real-time PCR, and next-generation sequencing (NGS). NGS has also offered the advantage of high-resolution typing, with deeper coverage of the HLA loci that allows the clinicians to identify the rare alleles and minimise the mismatches. Apart from this, the developments have also led to improved clinical outcomes and allowed for an expansion in the scope of personalized medicine applications, like precision immunotherapy. The use of automation and software-driven analysis tools has also helped in reducing the time of turnaround and the chance of human error, thus making HLA typing more accessible across laboratories and hospitals. The molecular diagnostics have also become more cost-effective and scalable, and therefore, the high-throughput HLA testing has been adopted in both clinical and research settings. Increasing Applications in Other Areas: Although the primary application of HLA typing is still transplantation, it has now seen increasing use in other areas as well, and that is helping to increase the demand in the market. HLA testing is being used in the field of pharmacogenomics to find the possible drug hypersensitivity reaction. 01 has been identified as a possible marker for abacavir-induced hypersensitivity, and HLA-B15:02 for carbamazepine-induced Stevens-Johnson syndrome. This has allowed the clinicians to design personalized treatment regimens and to avoid drug-induced adverse reactions, which is a primary goal of precision medicine. The HLA profiling has also found its use in autoimmune disease research, susceptibility to infectious diseases (HIV, COVID-19), and cancer immunotherapy – especially in finding the patient-specific neoantigens for the vaccine and T-cell therapy. With the increasing research in the immunogenetics and the novel therapies that are being developed, the importance of HLA typing extends beyond transplantation, and that will continue to drive the market. Stay Updated on The Latest HLA Typing Market Trends: Geographical Insights: North America holds a market share of 46.94% in the HLA typing market. The region is known for its strong academic foundation and prominent research centres, which is why it is also known for the largest contributor to the market. It is so because the rising prevalence of genetic disorders has been observed in the region, and that has led to the need for advanced healthcare facilities and research facilities. As a result, North America has one of the strongest networks of state-of-the-art medical institutions and research centres, giving it an unparalleled expertise in HLA typing. The government and industry leaders are also working to improve the organ transplantation in the region, and that has further strengthened the position of the region as the global hub for the specialized field. The Asia Pacific region is expected to witness a healthy growth in the human leukocyte antigen (HLA) typing market, as per the increasing improvements in healthcare infrastructure, comprehensive reimbursement policies, and the rising economic outlook. Presence of transplantation centers and skilled professionals will also boost the demand for HLA testing services. As laboratories continue to adopt advanced technologies, the region's HLA typing market is expected to witness substantial growth. Global HLA Typing Market Segmentation and Geographical Insights: Based on Product, the HLA Typing market is divided into, Instruments, Reagents & Consumables, and Software & Services. The human leukocyte antigen (HLA) reagents and consumables sector is poised for substantial growth, boasting a significant market share of 54.2% in 2022 and an impressive growth rate between 2023 and 2030. Based on Application, the HLA Typing market is divided into, Diagnosis, and Research. The diagnosis of Human Leukocyte Antigen (HLA) typing is poised to experience rapid growth, driven by the increasing demand for accurate disease detection. With a predicted CAGR of 6.8% over the forecast period, this segment is expected to outpace others in the market. Based on Technique, the HLA Typing market is divided into, Molecular Assay, Sequenced-based Molecular Assay, and Non-Molecular Assay. The molecular assay segment emerged as a leader in the market, boasting an impressive 53.0% share of the revenue. Based on End User, the HLA Typing market is divided into, Commercial Service Providers, Hospitals and Transplant Centres, and Research Labs & Academic Institutes. The market is predominantly driven by the growing presence of hospitals and transplant centres, accounting for a significant share of revenue, these facilities held an impressive 55.0% market stake. The HLA Typing Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global HLA Typing Market Size and Growth Report (2023-2030) at: Key Players and Competitive Landscape: The Global HLA Typing Market is characterized by the presence of several major players, including: Thermo Fisher Scientific Inc. Bio-Rad Laboratories Inc. Qiagen N.V. Omixon Inc. GenDx Illumina Inc. TBG Diagnostics Limited Dickinson and Company Takara Bio Inc. F. Hoffman-La Roche Limited Pacific Biosciences These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. Global HLA Typing Market Recent Developments and Innovations: In April 2025, Thermo Fisher Scientific launched the One Lambda HybriType Flex Kit, which aims to streamline HLA typing workflows by cutting total processing time to under 5.5 hours and hands-on time to less than 2.5 hours. In August 2024, Thermo Fisher Scientific received FDA 510(k) clearance for its SeCore CDx HLA a Sequencing System, approved as a companion diagnostic for TECELRA (afamitresgene autoleucel), a T-cell receptor therapy targeting synovial sarcoma. In October 2023, Roche launched the LightCycler PRO System based on the proven gold standard technology of the LightCycler Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in-vitro diagnostics. For Region-Specific Market Data, Check Out Brief Sample Pages: Frequently Asked Questions (FAQs): What is the forecasted market size of the HLA Typing Market in 2030?➢ The forecasted market size of the HLA Typing Market is USD 1.7 billion in 2030. Who are the leading players in the HLA Typing Market?➢ The key players in the HLA Typing Market include, Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.; Qiagen N.V.; Omixon Inc.; GenDx; Illumina Inc.; TBG Diagnostics Limited; Dickinson and Company; Takara Bio Inc.; F. Hoffman-La Roche Limited; and Pacific Biosciences. What are the major drivers for the HLA Typing Market? ➢ The growing need for organ transplantation and the extensive use of HLA testing in pharmacogenetics are expected to be key drivers of this growth. Which is the largest region during the forecasted period in the HLA Typing Market?➢ The North America stands out as a leader in the HLA typing market, accounting for 46.94% of the total share. Which is the largest segment, by end user, during the forecasted period in the HLA Typing Market?➢ The market is predominantly driven by the growing presence of hospitals and transplant centers, accounting for a significant share of revenue, these facilities held an impressive 55.0% market stake. Conclusion: Improvements in molecular diagnostics, next-generation sequencing (NGS), and bioinformatics are changing the HLA typing market as per the increasing need for transplantation, auto-immune diseases research, and pharmacogenomics. The increasing prevalence of chronic diseases, organ transplants, and the growing need for precision medicine have spurred the growth of high-resolution HLA typing methods. High resolution HLA typing methods can now provide increased accuracy, throughput, and speed, making them indispensable in donor-recipient matching and immunogenetic analysis. Digital platforms and cloud-based data solutions for integration help to access the analysis results in real-time and share them between institutions. The development of user-friendly software tools and automation in sample processing have helped in making laboratory workflow smooth. Along with the quality and standardization provided by the regulatory bodies, the market will continue to evolve with improved, more scalable, and cost-effective solutions. The HLA typing market will continue to be one of the major players in the growing trend of personalized medicine and advanced immunological research. Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: The report from The Research Insights, therefore, provides several stakeholders— healthcare providers, diagnostic laboratories, research institutions, regulatory agencies, and patients —with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 1.7 billion by 2030, the Global HLA Typing Market represents a significant opportunity for biotech startups, software developers, data analytics firms, and AI technology providers, can position themselves for success in this dynamic and evolving market landscape. Check out more related studies published by The Research Insights: Personalized Medicine Market: The Global Personalized Medicine Market is expected to reach at USD 909.80 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 8.2% during the forecast period. The rising prevalence of cancers and other diseases worldwide is driving the demand for innovative drug discovery solutions, a key factor contributing to the market's growth. Next-generation Sequencing Services Market - The global next-generation sequencing services market is poised to experience significant expansion, with an estimated USD 5.89 billion in revenue in 2023. At a compound annual growth rate (CAGR) of 22.68% from 2024 to 2030, the market is expected to continue growing rapidly. The integration of next-generation sequencing (NGS) technology into various applications has become increasingly widespread, enabling rapid and comprehensive insights at a genomic level. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Press Release: Latest News: | Logo: View original content: SOURCE The Research Insights Sign in to access your portfolio
CBS News
15-06-2025
- Health
- CBS News
Florida man back home after receiving second liver transplant at Chicago's Northwestern Medicine
A father of four is home in Florida for Father's Day thanks to the lifesaving surgery he received in Chicago. Andrew Wagner traveled to Northwestern Medicine for a second liver transplant following his battle with stage 1 lung cancer. Wagner won the battle, but learned his transplanted liver from 15 years ago was failing. As his condition got worse last year, his wife reached out to transplant centers across the country, hoping someone would agree to a second transplant. Since Wagner had not been cancer-free for three to five years, they were told the re-transplant was not an option. When they traveled to Chicago, Northwestern Medicine agreed to the surgery. "We're actually rewriting the textbook of indications for transplant here at Northwestern. It's really exciting times," said transplant surgeon Dr. Satish Nadig. "I always call this the renaissance of transplantation because what we're learning from the past is not necessarily what we're taking with us for the future of transplant." Five months after surgery, Wagner's new liver is functioning well, and he remains cancer-free. Now he's home with his wife, four daughters, and one granddaughter.
